Literature DB >> 19088024

Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma.

Liang Cheng1, Gregory T MacLennan, Shaobo Zhang, Mingsheng Wang, Ming Zhou, Puay-Hoon Tan, Stephanie Foster, Antonio Lopez-Beltran, Rodolfo Montironi.   

Abstract

PURPOSE: Renal cell carcinomas are often multifocal. We investigated the genomic signatures of multifocal clear cell renal cell carcinoma to determine whether multiple tumors in the same kidney bear a clonal relationship to one another. EXPERIMENTAL
DESIGN: A total of 62 tumors from 26 patients who underwent radical nephrectomy were examined. All patients had multiple separate clear cell renal carcinomas. Loss of heterozygosity analyses were done using five microsatellite polymorphic markers that represent putative tumor suppressor genes on chromosome 3p14 (D3S1300), 7q31 (D7S522), 8p22 (D8S261), 9p21 (D9S171), and 17p13 (TP53). X chromosome inactivation analyses were also done on the renal tumors from the 10 female patients. Chromosome 3p deletion status was determined by dual color interphase fluorescence in situ hybridization analysis in all tumors.
RESULTS: Nineteen of the 26 (73%) patients with multifocal clear cell renal cell carcinoma showed allelic loss in at least 1 of 5 microsatellite loci in separate tumors analyzed. A disconcordant pattern of allelic loss between coexisting kidney tumors was observed in 7 cases. Six cases showed discordant 3p deletion patterns by dual color interphase fluorescence in situ hybridization analysis. Of the eight informative female cases studied by X chromosome inactivation, one showed a discordant nonrandom pattern of X chromosome inactivation. Overall, evidence of independent origin of the multifocal renal tumors was observed in 12 of 26 cases (46%).
CONCLUSIONS: Our data suggest that in a significant number of cases of multifocal clear cell renal cell carcinoma, the spatially separate tumors are of different clonal origin and arise independently.

Entities:  

Mesh:

Year:  2008        PMID: 19088024     DOI: 10.1158/1078-0432.CCR-08-1494

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer.

Authors:  Jun Xiao; Jun-Xing Chen; Yu-Ping Zhu; Lin-Yu Zhou; Qi-An Shu; Ling-Wu Chen
Journal:  Oncol Lett       Date:  2012-04-05       Impact factor: 2.967

Review 2.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity.

Authors:  Sean R Williamson; Liang Cheng; John N Eble; Lawrence D True; Nilesh S Gupta; Mingsheng Wang; Shaobo Zhang; David J Grignon
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

5.  Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.

Authors:  Stephanie N Kinney; John N Eble; Ondrej Hes; Sean R Williamson; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lee Ann Baldrige; Guido Martignoni; Matteo Brunelli; Lisha Wang; Eva Comperat; Rong Fan; Rodolfo Montironi; Gregory T MacLennan; Liang Cheng
Journal:  Mod Pathol       Date:  2015-08-07       Impact factor: 7.842

6.  Renal cell carcinoma in tuberous sclerosis complex.

Authors:  Ping Yang; Kristine M Cornejo; Peter M Sadow; Liang Cheng; Mingsheng Wang; Yu Xiao; Zhong Jiang; Esther Oliva; Sergiusz Jozwiak; Robert L Nussbaum; Adam S Feldman; Elahna Paul; Elizabeth A Thiele; Jane J Yu; Elizabeth P Henske; David J Kwiatkowski; Robert H Young; Chin-Lee Wu
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

7.  Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Authors:  Lisha Wang; Sean R Williamson; Mingsheng Wang; Darrell D Davidson; Shaobo Zhang; Lee Ann Baldridge; Xiang Du; Liang Cheng
Journal:  Mol Cancer       Date:  2014-02-26       Impact factor: 27.401

8.  Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.

Authors:  Michal Kovac; Carolina Navas; Stuart Horswell; Max Salm; Chiara Bardella; Andrew Rowan; Mark Stares; Francesc Castro-Giner; Rosalie Fisher; Elza C de Bruin; Monika Kovacova; Maggie Gorman; Seiko Makino; Jennet Williams; Emma Jaeger; Angela Jones; Kimberley Howarth; James Larkin; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; Gordon Stamp; Tim O'Brien; Ben Challacombe; Nik Matthews; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Ignacio Varela; Ashish Chandra; Catherine Horsfield; Alexander Polson; Maxine Tran; Rupesh Bhatt; Luigi Terracciano; Serenella Eppenberger-Castori; Andrew Protheroe; Eamonn Maher; Mona El Bahrawy; Stewart Fleming; Peter Ratcliffe; Karl Heinimann; Charles Swanton; Ian Tomlinson
Journal:  Nat Commun       Date:  2015-03-19       Impact factor: 14.919

9.  A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity.

Authors:  Qing Yan Xie; Anthony Almudevar; Christa L Whitney-Miller; Christopher T Barry; Matthew N McCall
Journal:  BMC Med Genomics       Date:  2016-04-08       Impact factor: 3.063

10.  Multifocal Primary Neoplasms in Kidney Allografts: Evaluation of Two Cases.

Authors:  Robert J Ellis; Keng Lim Ng; Hemamali Samaratunga; Sharon J Del Vecchio; Simon T Wood; Glenda C Gobe
Journal:  J Kidney Cancer VHL       Date:  2016-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.